PMID: 8581408Sep 1, 1995Paper

Immunological effects of the anti-IL-2 receptor monoclonal antibody BT 563 in liver allografted patients

Transplant Immunology
B NashanR Pichlmayr

Abstract

The immunological effects of therapeutic monoclonal antibodies (mAbs) depend upon their interaction with the target structure as well as the isotype of the mAb which is responsible for the binding to Fc receptors of accessory cells. The aim of the presented analysis was the evaluation of the in vivo immunosuppressive effect of BT 563, a mAb directed to the alpha-chain of the interleukin-2 receptor (IL-2R). Thirty-eight patients following liver transplantation were treated prophylactically for 12 days with 10 mg/day BT 563 (clinical phase II and III study). As baseline immunosuppression cyclosporin (CyA) and low dose steroids were administered. BT 563 levels, lymphocyte subpopulations, levels of soluble CD25 and Fc receptor polymorphism were evaluated and compared to the clinical outcome. Preoperatively in all patients a small subset of CD45R0+ cells expressed CD25 with detectable density. These cells were coated by BT 563. There was no evidence for depletion of IL-2R+ cells or modulation of the IL-2R. During therapy stable levels of the soluble IL-2R were measured in patient sera. Throughout the therapy high levels of unbound BT 563 were found in sera, suggesting that IL-2R newly expressed on cells activated by the allograft co...Continue Reading

References

Jun 4, 1992·Nature·A L Goldberg, K L Rock
May 1, 1992·The Journal of Experimental Medicine·J P NorthropP S Mattila
Jul 17, 1992·Science·T TakeshitaK Sugamura
Oct 1, 1991·European Journal of Immunology·A N AkbarG Janossy
Jan 1, 1990·Advances in Immunology·A AltmanT Mustelin
Jun 1, 1990·The Journal of Investigative Dermatology·W A Kuziel, W C Greene
Jan 1, 1991·The Journal of Experimental Medicine·M J DallmanP J Morris
Nov 1, 1981·The Journal of Experimental Medicine·R J RobbK A Smith
Feb 1, 1993·Scandinavian Journal of Immunology·J SteinmannW Müller-Ruchholtz
Mar 1, 1993·The Journal of Experimental Medicine·M J WoodH M Charlton

❮ Previous
Next ❯

Citations

Oct 8, 2003·Transplantation Proceedings·A Debska-SlizieńB Rutkowski
Nov 1, 2001·Radiology·E M MaromH P McAdams
Jul 19, 2002·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Gerit NiemeyerBjoern Nashan
Dec 3, 2009·Transplant International : Official Journal of the European Society for Organ Transplantation·Florian Wolfgang Rudolf VondranReinhard Schwinzer
Aug 1, 2008·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·P V SuneethaHeiner Wedemeyer
May 31, 2015·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Qin QinMin Zhao
Feb 28, 2002·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Ryutaro Hirose
Jun 6, 2014·The Cochrane Database of Systematic Reviews·Luit PenningaChristian Gluud
Jun 1, 2014·The Cochrane Database of Systematic Reviews·Luit PenningaChristian Gluud
Aug 8, 1998·Clinical Pharmacology and Therapeutics·J KovarikB Nashan
Jan 1, 1996·International Journal of Urology : Official Journal of the Japanese Urological Association·H M Lee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.